| You are here: Home: BCU 4|2004: Martine Piccart, MD, PhD and Larry Norton, MD: Select publications
Select publications
Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract
Boccardo F etal. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer ResTreat 2003;82(Suppl 1); Abstract 3.
Citron ML etal. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. Breast CanRes Treat 2002;76(Suppl 1):31;Abstract 12.
Lear-Kaul KCetal. Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 2003;127(11):1451-7. Abstract
Leyland-Jones B et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21(21):3965-71. Abstract
Lindrud S et al. Central nervous system progression during systemic response to trastuzumab, . humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer. Breast J 2003;9(2):116-9. Abstract
Lower EE et al. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003;4(2):114-9. Abstract
Lyman GHetal. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21(24):4524-31. Abstract
Osoba D etal. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002;20(14):3106-13. Abstract
Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18(11):2349-51. No abstract available
Shmueli E et al. Central nervous system progression among patients with metastatic breast cancer . responding to trastuzumab treatment. Eur J Cancer 2004;40(3):379-82. Abstract
Slamon DJ etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Therasse P etal,on behalf of the European Organization for Research and Treatment of Cancer. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21(5):843-50. Abstract
Vogel CL etal. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
|
